GSK has acquired an approval for ‘Incruse Ellipta,’ reinforcing its COPD lineup
GSK is in the heat of reinforcing its respiratory disease treatment pipeline. It is working on a long-acting anticholinergic(LAMA) drug this time.
The company has acquired a sales approval for the LAMA-only chronic obstructive pulmonary disease(COPD) treatment, ‘Incruse Ellipta(umeclidinium),’ f...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
